Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2025)

Stoke Therapeutics has reported Current Deferred Revenue over the past 4 years, most recently at $11.9 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $11.9 million for Q4 2025, down 37.33% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (down 37.33% YoY), and the annual figure for FY2025 was $11.9 million, down 37.33%.
  • Current Deferred Revenue for Q4 2025 was $11.9 million at Stoke Therapeutics, up from $5.8 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for STOK hit a ceiling of $31.6 million in Q3 2024 and a floor of $5.8 million in Q3 2025.
  • Median Current Deferred Revenue over the past 4 years was $13.1 million (2022), compared with a mean of $14.7 million.
  • Biggest five-year swings in Current Deferred Revenue: soared 261.9% in 2024 and later plummeted 81.77% in 2025.
  • Stoke Therapeutics' Current Deferred Revenue stood at $14.9 million in 2022, then rose by 2.88% to $15.3 million in 2023, then rose by 24.05% to $19.0 million in 2024, then plummeted by 37.33% to $11.9 million in 2025.
  • The last three reported values for Current Deferred Revenue were $11.9 million (Q4 2025), $5.8 million (Q3 2025), and $8.7 million (Q2 2025) per Business Quant data.